Drug Approval | September 06, 2021
DGCI approves Hetero’s Tocilizumab
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
At present 18 per cent of the local pharmaceutical market is under government's price control
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across eight sites in Maharashtra
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The trial will be conducted across 10 sites in India
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Subscribe To Our Newsletter & Stay Updated
